Acura Pharmaceuticals ( (ACUR) ) has released a notification of late filing.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Acura Pharmaceuticals has filed a Form 12b-25 to notify the delay in submitting its Form 10-Q (Quarter Report) for the financial period ending March 31, 2025. The primary reason for the delay is the company’s ongoing liquidity issues, which have affected its ability to meet day-to-day operational obligations. Acura Pharmaceuticals is dependent on loans from Abuse Deterrent Pharma, LLC to sustain operations, but there is no assurance that these loans will continue or be adequate for long-term needs. The company has also not filed its Annual Reports for 2022, 2023, and 2024, nor its Quarterly Reports for those years. A new independent registered public accounting firm was appointed in February 2024, but the review and audit services have been delayed due to funding issues. Acura Pharmaceuticals anticipates filing the delayed report within five calendar days following the prescribed due date. The company does not expect any significant changes in its financial results from the previous fiscal period. The notification was signed by Robert A. Seiser, SVP & CFO, on May 14, 2025, and the company continues to work on compliance efforts.
More about Acura Pharmaceuticals
Average Trading Volume: 8,025
Technical Sentiment Signal: Sell
Current Market Cap: $1.32M
See more data about ACUR stock on TipRanks’ Stock Analysis page.